Table 1 Patient demographics and clinical characteristics
Total (n = 58) | FEV1% predicted ≥ median (n = 29) | FEV1% predicted < median (n = 29) | P-value | |
|---|---|---|---|---|
Age, years range | 18 - 61 | 18 - 49 | 19 - 61 | < 0.01 |
Sex, male n (%) | 34 (58.62) | 18 (62.1) | 16 (55.2) | 0.79 |
BMI, kg/m2 ± SD | 23.24 ± 3.25 | 24.2 ± 3.4 | 22.3 ± 2.9 | 0.02 |
FEV1, % predicted ± SD | 71.93 ± 24.80 | 92.9 ± 12.9 | 51.0 ± 13.2 | - |
Current medications | ||||
Azithromycin, n (%) | 18 (31.03) | 3 (10.3) | 15 (51.7) | < 0.01 |
Ciprofloxacin, n (%) | 2 (3.45) | 1 (3.4) | 1 (3.4) | 1.00 |
Dornase alfa, n (%) | 24 (41.38) | 11 (37.9) | 13 (44.8) | 0.79 |
Ibuprofen, n (%) | 2 (3.45) | 2 (6.9) | 0 (0) | 0.49 |
Prednisone, n (%) | 0 (0) | 0 (0) | 0 (0) | - |
Tobramycin, n (%) | 13 (22.41) | 2 (6.9) | 11 (37.9) | 0.01 |
Inhaled steroids, n (%) | 37 (63.79) | 15 (51.7) | 22 (75.9) | 0.10 |
Diabetes, n (%) | 22 (37.93) | 10 (34.5) | 12 (41.4) | 0.79 |
Hospitalization, n (%) | 21 (36.2) | 6 (20.7) | 15 (51.7) | 0.03 |
Pseudomonas, n (%) | 42 (72.41) | 15 (51.7) | 27 (93.1) | < 0.01 |